SilicoScientia at IPC 2025
We presented our poster at IPC 2025, highlighting SilicoXplore — an integrated AI- and physics-driven in silico drug discovery platform that unifies virtual screening, activity prediction, toxicity assessment, and lead optimization into a single workflow for faster, cost-effective, data-driven early drug discovery.
The featured case study applied the full pipeline to EGFR-targeted glioblastoma treatment — narrowing millions of compounds down to a shortlist of promising EGFR-targeting candidates.
Read the announcement on LinkedIn